This agent exerts its antimyeloma activity through several actions including unfolded protein stress response induction [10], NF-κB prosurvival activity downregulation [11], modification of bone turnover and the bone marrow microenvironment leading to increased bone strength and compromised microenvironmental support for myeloma cells [12–14], and induction of immunogenic myeloma cell death through increased natural kill cell-mediated MM-cell lysis and enhanced antigen presentation (Fig. 1) [12–17]. The gene discussed is NFKB1; the disease is plasma cell myeloma.